Literature DB >> 11557779

Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections.

P C Burger1, A Y Minn, J S Smith, T J Borell, A E Jedlicka, B K Huntley, P T Goldthwaite, R B Jenkins, B G Feuerstein.   

Abstract

Comparative genomic hybridization (CGH), fluorescence in situ hybridization (FISH), polymerase chain reaction-based microsatellite analysis, and p53 sequencing were performed in paraffin-embedded material from 18 oligodendrogliomas and histologically similar astrocytomas. The study was undertaken because of evidence that concurrent loss of both the 1p and 19q chromosome arms is a specific marker for oligodendrogliomas. Of the six lesions with a review diagnosis of oligodendroglioma, all had the predicted loss of 1p and 19q seen by CGH, FISH, and polymerase chain reaction. Other lesions, including some considered oligodendroglioma or mixed glioma by the submitting institution, did not. There were no p53 mutations in any of the six oligodendrogliomas, whereas 5 of the 10 remaining, successfully studied cases did have p53 mutations. The results suggest that CGH and FISH performed on current or archival tissue can aid in classification of infiltrating gliomas such as oligodendrogliomas and astrocytomas. The results of the p53 studies are consistent with findings of previous investigations that such mutations are less common in oligodendrogliomas than they are in astrocytomas.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11557779     DOI: 10.1038/modpathol.3880400

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  28 in total

Review 1.  Molecular diagnostics: techniques and recommendations for 1p/19q assessment.

Authors:  Adelheid Woehrer; Johannes A Hainfellner
Journal:  CNS Oncol       Date:  2015-11-06

2.  1p/19q-driven prognostic molecular classification for high-grade oligodendroglial tumors.

Authors:  Haihui Jiang; Zhe Zhang; Xiaohui Ren; Wei Zeng; Wenqing Jia; Junmei Wang; Song Lin
Journal:  J Neurooncol       Date:  2014-08-24       Impact factor: 4.130

3.  Limited tissue fixation times and whole genomic amplification do not impact array CGH profiles.

Authors:  A A Ghazani; N C R Arneson; K Warren; S J Done
Journal:  J Clin Pathol       Date:  2006-03       Impact factor: 3.411

Review 4.  Management of newly diagnosed glioblastoma: guidelines development, value and application.

Authors:  Jeffrey J Olson; Camilo E Fadul; Daniel J Brat; Srinivasan Mukundan; Timothy C Ryken
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

5.  Diagnosis of malignant glioma: role of neuropathology.

Authors:  Daniel J Brat; Richard A Prayson; Timothy C Ryken; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2008-08-20       Impact factor: 4.130

6.  Oligodendroglial-specific transcriptional factor SOX10 is ubiquitously expressed in human gliomas.

Authors:  Sergei I Bannykh; C Claus Stolt; Jung Kim; Arie Perry; Michael Wegner
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

7.  Chromosomal defects track tumor subpopulations and change in progression in oligodendroglioma.

Authors:  David W Nauen; Andrew Guajardo; Lisa Haley; Kerry Powell; Peter C Burger; Christopher D Gocke
Journal:  Converg Sci Phys Oncol       Date:  2015-06-16

Review 8.  Pathology and molecular genetics of oligodendroglial tumors.

Authors:  Christian Hartmann; Wolf Mueller; Andreas von Deimling
Journal:  J Mol Med (Berl)       Date:  2004-10       Impact factor: 4.599

9.  Assessment of tumor angiogenesis as a prognostic factor of survival in patients with oligodendroglioma.

Authors:  H Quon; A Hasbini; J Cougnard; L Djafari; C Lacroix; B Abdulkarim
Journal:  J Neurooncol       Date:  2009-07-19       Impact factor: 4.130

10.  Molecular diagnosis of metastasizing oligodendroglioma: a case report.

Authors:  Min Wang; Kathleen M Murphy; Piotr Kulesza; Kimmo J Hatanpaa; Alessandro Olivi; Anthony Tufaro; Yener Erozan; William H Westra; Peter C Burger; Karin D Berg
Journal:  J Mol Diagn       Date:  2004-02       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.